Amgen Q2 Earnings Beat Estimates, Shares Fall Amid MariTide Focus
ByAinvest
Wednesday, Aug 6, 2025 2:21 pm ET1min read
AMGN--
Key highlights of the quarter include:
- Product Sales Growth: Fifteen products experienced double-digit sales growth, with Repatha® (evolocumab) and EVENITY® (romosozumab-aqqg) leading the way, increasing by 31% and 32% YoY, respectively [1].
- Operating Income and Margin: GAAP operating income rose from $1.9 billion to $2.7 billion, while the operating margin increased 6.6 percentage points to 30.3% [1].
- Non-GAAP Metrics: Non-GAAP EPS increased 21% to $6.02, and non-GAAP operating income rose to $4.3 billion, with the operating margin expanding 0.7 percentage points to 48.9% [1].
- Free Cash Flow: The company generated $1.9 billion in free cash flow, down from $2.2 billion in the previous year, primarily due to deferred tax payments and higher capital expenditures [1].
Amgen also raised its full-year 2025 adjusted earnings guidance to $20.20-$21.30 per share and sales outlook to $35-$36 billion [1]. However, investor focus remains on the experimental weight-loss drug MariTide, with data readout anticipated in the fourth quarter of 2025 [1].
Despite the positive results, Amgen shares are trading lower by 5.10% to $284.97 as of July 2, 2025, reflecting market concerns about the potential impact of biosimilar competition and the upcoming MariTide data readout [1].
References:
[1] Amgen Reports Second Quarter 2025 Financial Results. (2025, August 5). PRNewswire. Retrieved from https://www.amgen.com/newsroom/press-releases/2025/08/amgen-reports-second-quarter-2025-financial-results
Amgen reported Q2 earnings of $6.02 per share, up 21% YoY, beating expectations. Sales rose 9% to $9.18 billion, exceeding estimates. The company raised FY25 adjusted earnings guidance to $20.20-$21.30 and sales outlook to $35-$36 billion. Despite positive results, investor focus remains on experimental weight-loss drug MariTide, with data readout anticipated in Q4 2025. Amgen shares are trading lower by 5.10% to $284.97.
Amgen (NASDAQ: AMGN) announced its second-quarter 2025 financial results, showcasing robust performance across various therapeutic areas. The company reported earnings per share (EPS) of $6.02, up 21% year-over-year (YoY), exceeding analysts' expectations of $5.75 [1]. Total revenues increased 9% to $9.2 billion, driven by 13% volume growth, partially offset by a 3% decrease in net selling price [1].Key highlights of the quarter include:
- Product Sales Growth: Fifteen products experienced double-digit sales growth, with Repatha® (evolocumab) and EVENITY® (romosozumab-aqqg) leading the way, increasing by 31% and 32% YoY, respectively [1].
- Operating Income and Margin: GAAP operating income rose from $1.9 billion to $2.7 billion, while the operating margin increased 6.6 percentage points to 30.3% [1].
- Non-GAAP Metrics: Non-GAAP EPS increased 21% to $6.02, and non-GAAP operating income rose to $4.3 billion, with the operating margin expanding 0.7 percentage points to 48.9% [1].
- Free Cash Flow: The company generated $1.9 billion in free cash flow, down from $2.2 billion in the previous year, primarily due to deferred tax payments and higher capital expenditures [1].
Amgen also raised its full-year 2025 adjusted earnings guidance to $20.20-$21.30 per share and sales outlook to $35-$36 billion [1]. However, investor focus remains on the experimental weight-loss drug MariTide, with data readout anticipated in the fourth quarter of 2025 [1].
Despite the positive results, Amgen shares are trading lower by 5.10% to $284.97 as of July 2, 2025, reflecting market concerns about the potential impact of biosimilar competition and the upcoming MariTide data readout [1].
References:
[1] Amgen Reports Second Quarter 2025 Financial Results. (2025, August 5). PRNewswire. Retrieved from https://www.amgen.com/newsroom/press-releases/2025/08/amgen-reports-second-quarter-2025-financial-results
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet